CAPTOR THERAPEUTICS SPOLKA AKCYJNA

Communiqués Captor Therapeutics Spolka Akcyjna

Actions

CTX

PLCPTRT00014

Marché Fermé - Warsaw S.E. Autres places de cotation 17:55:47 04/07/2024			Varia. 5j.	Varia. 1 janv.
71,8 ^PLN	-2,45%		-9,34%	-27,47%

29/05	Captor Therapeutics Spolka Akcyjna annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
2023	Captor Therapeutics Spolka Akcyjna annonce ses résultats pour les neuf mois clos le 30 septembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Captor Therapeutics Publishes Q1 2023 Financial Results	30/05/23	AQ
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast	28/03/23	AQ
Captor Therapeutics Announces Three-Year Strategic Objectives	07/03/23	AQ
Captor Therapeutics Reports Q3 2022 Results and Provides Business UpdateLead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical	28/11/22	AQ
Captor Therapeutics Reports Q3 2022 Results and Provides Business Update	25/11/22	AQ
Ono Enters a Drug Discovery Collaboration Agreement with Captor Therapeutics to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases	15/11/22	AQ
Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases	14/11/22	AQ
Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma	10/08/22	AQ
Captor Therapeutics to Host R&D Day on May 18, 2022	05/05/22	GL
Captor Therapeutics to Host R&D Day on May 18, 2022	05/05/22	AQ
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma	12/04/22	AQ
Captor Therapeutics Invited to TPD Panel at the 8th Annual LSX World Congress 2022	11/04/22	GL
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma	13/01/22	GL
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma	13/01/22	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Bourse
Actions
Action CTX
Actualités Captor Therapeutics Spolka Akcyjna
Communiqués

Nos Contenus Gratuits vous Aident à Sécuriser et Augmenter la Performance de vos Investissements

Sécuriser mes Investissements

fermer